Arrowhead Research Corp. Stockholders Who Suffered Losses in Excess of $100,000 Encouraged to Contact Securities Law Firm about Investigation

NEW YORK, Oct. 15, 2014 /PRNewswire/ -- Securities lawyers at Dunnam & Dunnam are investigating allegations for Arrowhead Research Corp. shareholders (NASDAQ MKT: ARWR). Concerned ARWR investors who purchased between March 24, 2014 and October 8, 2014 are encouraged to contact securities attorney Hamilton Lindley by clicking here.

The law firm's investigation will focus on Arrowhead Research Corp.'s release of disappointing data from its experimental hepatitis B therapy ARC-520.  On October 8, 2014, it was reported that Arrowhead knew for months that ARC-520 dosed at 1 mg/kg and 2mg/kg yielded 0.2-log and 0.3-log reductions in hepatitis B viral load.  Yet, despite this knowledge, Arrowhead allegedly misled investors to believe that ARC-520 was more potent and achieved viral load reductions in the range of 0.7 log or higher.  On this news, shares of Arrowhead Research fell $5.48 per share, or over 43%, to close at $7.03 per share on October 8, 2014.

Dunnam & Dunnam has significant experience representing shareholders in securities lawsuits nationwide. ARWR stockholders – or anyone with knowledge about this situation – should contact lawyer Hamilton Lindley at [email protected] with questions or concerns toll free at 844-702-2990 or visit http://www.dunnamlaw.com/ARWR.

SOURCE Dunnam & Dunnam

Related Links

http://www.dunnamlaw.com